Cullinan Oncology Inc
NASDAQ:CGEM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
W R Berkley Corp
NYSE:WRB
|
US |
|
Nexoptic Technology Corp
XTSX:NXO
|
CA |
|
B
|
Beijing Succeeder Technology Inc
SSE:688338
|
CN |
|
B
|
Bloom Energy Corp
SWB:1ZB
|
US |
|
Z
|
Zephyrus Wing Energies Ltd
TASE:ZPRS
|
IL |
|
Biomerieux SA
OTC:BMXMF
|
FR |
Cullinan Oncology Inc
Other Items
Cullinan Oncology Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cullinan Oncology Inc
NASDAQ:CGEM
|
Other Items
$180m
|
CAGR 3-Years
26%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Items
-$5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Items
-$4.2B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Items
-$85m
|
CAGR 3-Years
74%
|
CAGR 5-Years
55%
|
CAGR 10-Years
33%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Items
-$507.8m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Items
$584.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Cullinan Oncology Inc
Glance View
Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2021-01-08. The firm is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081 in a Phase I/IIa, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.
See Also
What is Cullinan Oncology Inc's Other Items?
Other Items
-136.3m
USD
Based on the financial report for Dec 31, 2024, Cullinan Oncology Inc's Other Items amounts to -136.3m USD.
What is Cullinan Oncology Inc's Other Items growth rate?
Other Items CAGR 5Y
-31%
The average annual Other Items growth rates for Cullinan Oncology Inc have been 26% over the past three years , -31% over the past five years .
